DrugInjuryLegal.com
Important statute of limitations deadline regarding your Bextra case - April 6, 2008, Contact attorney Casey J. Flynn (direct: 314-678-1207) for a Free Case Evaluation of your heart attack, stroke, and SJS Bextra case. Click here for Free Case Evaluation.

Bextra

Important statute of limitations deadline regarding your Bextra case - April 6, 2008: The pain relieving drug Bextra, manufactured by Pfizer Pharmaceuticals, was pulled from the market on April 7, 2005, after the FDA determined Bextra posed too high a risk of adverse cardiovascular events, as well as potentially fatal skin reactions such as Stevens Johnson Syndrome. Therefore if you have suffered a heart attack, stroke or permanent rash because of your use of Bextra, your statute of limitations could expire on April 6, 2008. Contact attorney Casey J. Flynn (direct: 314-678-1207) for a Free Case Evaluation. Submit form for Free Case Evaluation.

Importantly, the below states have a three year statute of limitations for your Bextra claim:  Arkansas, District of Columbia, Florida, Maine, Maryland, Massachusetts, Michigan, Mississippi, Missouri, Montana, Nebraska, New Hampshire, New Mexico, New York, N. Carolina, N. Dakota, Rhode Island, S. Carolina, S. Dakota, Utah, Washington, and Wyoming.

Stevens Johnson syndrome (SJS) is characterized by the development of circular mucocutaneous lesions (target lesions) that cover the skin.
With Stevens Johnson Syndrome, the skin and mucous membranes become severely inflamed. The rash may often develop with blisters at the center. The red rash usually breaks out on the face and torso of the body and begins to spread from there. The skin condition also causes sores on mucous membranes of the eyelids, mouth, nose, genitals and possibly gastrointestinal and lower respiratory tract mucous membranes.

Bextra is Toxic Epidermal Necrolysis. Toxic epidermal necrolysis is a serious skin disease that if not properly treated has the potential to be life threatening. Toxic epidermal necrolysis, also referred to as TEN, is very similar to the skin disorder known as Stevens Johnson syndrome. Similarly to Stevens Johnson syndrome, toxic epidermal necrolysis also involves the development of a rash that spreads throughout the body. Toxic epidermal necrolysis, like Stevens Johnson syndrome, also involves the growth of blisters or sores on the mucous membranes of the eyelids, nose, mouth, genitals, and gastrointestinal and lower respiratory tract.

Stevens-Johnson syndromeand other skin reactions in Bextra patients. Thirty-six of these Bextra patients were hospitalized due to these side effects while four patients have died. As a result of the link between these skin conditions and Bextra, along with cardiovascular side effects attributed to the drug, Bextra was voluntarily removed from the market by Pfizer in April of 2005, at the request of the FDA.

If you or someone in your family is suffering from Steven Johnson Syndrome, Toxic Epidermal Necrolysis or have a permanent rash that resulted while you were on Bextra, or if you suffered a heart attack or stroke while on Bextra, you may be entitled to a substantial recovery.
Submit form for Free Case Evaluation.